吉西他滨联合奈达铂治疗晚期肺鳞癌的疗效观察

Curative Effect Observation of Gemcitabine Combined with Nedaplatinin the Treatment of Advanced Lung Squamous Cell Carcinoma

目的探讨吉西他滨联合奈达铂对肺鳞癌患者的临床疗效和安全性,以及对患者生活质量的影响。方法74例晚期肺鳞癌患者随机分为两组,分别采用吉西他滨联合奈达铂治疗和吉西他滨联合顺铂治疗,比较两组有效率、毒副反应和生活质量。结果吉西他滨联合奈达铂组有效率(RR)为54.10%,吉西他滨联合顺铂组有效率(RR)为59.46%,两组间有效率差异无统计学意义(P>0.05);试验组Ⅱ~Ⅳ粒细胞下降率为45.95%,对照组为24.32%,差异有统计学意义(P<0.05);试验组Ⅱ~Ⅳ恶心、呕吐发生率为18.92%,对照组为43.24%,差异有统计学意义(P<0.05);其余各不良反应发生率差异无统计学意义(P>0.05)。治疗3个月,两组患者躯体功能、角色功能、情感功能、认知功能、社会功能及整体健康状况评分较本组治疗前增加,乏力、食欲减退、气促、咳嗽、胸痛等症状评分较治疗前降低,差异有统计学意义(P<0.05),但观察组患者较对照组改善更明显,差异有统计学意义(P<0.05)。结论吉西他滨联合奈达铂能显著减轻胃肠道毒性,有利于改善患者生活质量。

Objective To investigate the clinical effect, safety and influence on quality of life of gemcitabine combined with nedaplatin in the treatment of advanced lung squamous cell carcinoma. Methods 74 cases patients with advanced lung squa- mous cell carcinoma were randomly divided into experimental group（ treated with gemcitabine combined with nadaplatin）, and con- trol group（ treated with gemeitabine combined with cisplatin）. The efficiency, toxicity and quality of life of two groups were com- pared. Results The RR in experimental group was 54. 10% and 59. 46% in control group （ P 〉 0.05 ）. The decrease rate of gran- ulocyte in experimental group was 45.95 % , and 24. 32% in control group （ P 〈 0. 05 ）. The incidence of nausea and vomiting in ex- perimental group was 18. 92% ,and 43.24% in control group（P 〈0. 05）. There was no significant difference in the incidence of other adverse reaetions（P 〉 0. 05 ）. Two groups of patients score higher than before in physical function, role function, emotional function, cognitive function, social function and overall health while lower in fatigue, loss of appetite, shortness of breath, cough, chest pain and other symptoms （P 〈 0. 05 ）. But compared with the control group, the improvement of experimental group was more obvious （P 〈 0. 05 ）. Conclusion Gemcitabine combined with nedaplatin could significantly reduce gastrointestinal toxicity and improve the quality of life of patients.